Pharmavite, FDA Offer Alternate Takes On GMP Compliance Strategy
This article was originally published in The Tan Sheet
A Pharmavite executive outlined a “different perspective” from the conventional wisdom promoted by FDA on successful compliance with dietary supplement good manufacturing practices: an emphasis on finished product specifications.
You may also be interested in...
A year after the final step in the three-year rollout of the dietary supplement good manufacturing practices final rule, firms large and small are learning the hard way what FDA expects to find in a facility.
Some dietary supplement firms will not be ready to comply with good manufacturing practices by the rapidly approaching final deadline, according to a senior FDA advisor on supplement products
Among four FDA regulatory items withdrawn from OMB review is “Cannabidiol Enforcement Policy; Draft Guidance for Industry,” which the agency submitted in July 2020.